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Abstract: Hyaluronan is the major extracellular matrix glycosaminoglycan 
polymer present in vertebrate tissues, with a molar mass that can reach sev-
eral megaDaltons. It is particularly prominent in the matrix of tissues under-
going rapid turnover, in fetal tissues, and wherever regeneration and repair 
are occurring. Hyaluronan has highly varied biological functions often de-
pendent on molar mass, however they are highly dependent on source of 
hyaluronan, its purity and nature of contaminants. Hyaluronan of high-
molar-mass is known for its anti-angiogenic, anti-inflammatory and immu-
nosuppressive properties, unlike hyaluronan of low-molar-mass that has the 
opposite effects. Hyaluronan also has a broad range of clinical applications, 
such as intra-articular injection, in ophthalmology, otolaryngology, wound healing, and 
commercially in the cosmetic industry, as well as in drug delivery systems. Currently, 
polymers of hyaluronan are modified in order to improve their properties, including 
bioavailability and resistance to degradation. Because of greatly increased interest currently 
in hyaluronan, the multiple functions of the polymer are presented here, including medicine 
and industry, as well as recent progress in the formulation of hyaluronan-based materials. 
Keywords: Hyaluronic acid, hyaluronan production, tissue engineering, viscoelasticity, viscosupplemenation, vis-
coprotection. 
INTRODUCTION 
Hyaluronan (hyaluronic acid, HA, Fig. 1a, 1c), 
a linear polymer composed of two disaccharides-D-
glucuronic acid and N-acetyl-D-glucosamine, is linked 
via β-1,4 and β-1,3 glycosidic bonds. Unlike other 
GAGs (glycosaminoglycans), HA lacks a sulfate group. 
The number of disaccharide units in HA can vary from 
25 to 25,000, with a linear uncoiled polymer length 
from 10 nm to 25 µm [1]. Molar mass of HA reaches 
from 100 kDa in serum to 8 MDa in the vitreous of the 
eye [2] (Table 1). 
In addition, various aspects of the metabolism of 
HA are indicated in Table 1 for purposes of orientation. 
The biological significance of the tetrasaccharide and  
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Fig. (1). A highly viscous solution of HA; an adult naked 
mole rat [36]; structure of HA demonstrating a tetrasac- 
charide or two repeating units of N-acetyl-D-glucosamine 
and D-glucuronic acid. 
 
the oligomeric HA with ~ 25 disaccharide units within 
the metabolic cycle are pointed out. A remarkable 
property of HA is its capacity to surround itself with a 
large volume of water that can reach up to several 
thousand-fold its original weight [3-6]. The very large 
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negative charge associated with HA at neutral pH ac-
counts for this extraordinary water domain. In Table 1 
the hydrodynamic radius (Rh) and the gyration radius 
(Rg), related to HA molecules in the dissolved state, are 
also provided [7-10]. 
In 1934, Meyer and Palmer became the first to pu-
rify a substance that was later identified as HA, isolat-
ing it from the bovine vitreous body [11]. It took an-
other 20 years to solve its chemical structure. HA to-
gether with cellulose and chitin constitute the three ma-
jor β-chain sugar polymers on Earth [12]. However, 
cellulose and chitin, homopolymers of glucose and N-
acetyl-D-glucosamine respectively, contain exclusively 
linkage by β-1,4 bonds. It is the interspersed β-1,3 
bonds that provide the HA polymer with its enormous 
flexibility and solubility. HAs can associate physio-
logically in various manners, either electrostatically or 
covalently, to form a remarkable variety of forms and 
structures: single self-associating molecules, as a moi-
ety that binds to proteins (referred to as hyaladherins), 
or other GAGs, ability to form fibers, cables, fibrous 
networks, sheets, stacks, as space-filling volume ex-
panders that functions as shock absorbers, or as resis-
tance to compression. An example of the latter is the 
Wharton’s jelly of the umbilical cord. It is 99% HA, 
and prevents vessel compression during neonatal deliv-
ery. The smaller HAs are able to aggregate or self-
associate as readily as the higher-molar-mass polymers, 
following complex size-dependent formulas that are 
not well understood.  
HA occurs as the predominant component in the 
ECM (extracellular matrix) of almost every tissue of 
vertebrates, particularly in the umbilical cord, skin, vit-
reous of the eye, and in heart valves. Additionally, high 
concentrations of HA are present in lymphatic and 
synovial fluid (SF) and in brain [13-16]. HA also oc-
curs intracellularly but its function therein remains un-
clear [17]. The concentrations of HA in several human 
organs as well as in that of other mammals are pro-
vided in Table 2 [18]. 
HA is involved in cell migration, adhesion, prolif-
eration and differentiation, in other physiological proc-
esses including embryological development, wound 
healing, regeneration and repair, and whenever rapid 
tissue growth occurs. It functions through a broad 
range of signal transduction pathways [19, 20]. At a 
body-wide scale, HA modulates water homeostasis, 
maintains osmotic pressure, buffers physiological solu-
Table 1. The size, uncoiled length, radius of gyration, hydrodynamic radius, and molar mass of HA molecules [7-10]. 
Physiological moiety Number of di-
saccharide units 
Uncoiled length Radius of gyration, 
Rga(nm) 
Hydrodynamic 
radius, Rhb(nm) 
Molar mass (Da) 
1 10 Å - - 400 
2 20 Å - - 800 
HYAL 1 cleavage 
productc 
10 10 nm ~ 3.8 ~ 2.4 4.0 × 103 
HYAL 2 cleavage 
productd 25 25 nm ~ 6.7 ~ 4.2 1 × 10
4 
Serum HA  75 75 nm ~ 12.9 ~ 8.1 3 × 104 
250 250 nm ~ 26.5 ~ 16.6 1 × 105 
2,500 2.5 µm ~ 106 ~ 66.3 1 × 106 
High-molar-mass HAs 
10,000 10e µm ~ 242 ~ 151 4 × 106 
HA in the vitreous of 
the eye 25,000 25.0 µm ~ 420 ~ 263
f 1 × 107 
aRg in 0.2M aqueous NaCl.  
bSince Rg/Rh = 1.5-1.8 for linear flexible chain of hyaluronan, an approximate estimation of the hydrodynamic radius Rh = Rg/1.6 (R. Mendichi, personal 
communication). 
cThe tetrasaccharide is the predominant cleavage product of hyaluronidase-1 (HYAL 1), the acid-active lysosomal enzyme. The tetrasaccharide corresponds to 
the size that fits precisely into the active site of the enzyme [7].  
dHyaluronidase-2 (HYAL 2) is the first enzyme encountered by the large HA of the ECM. The enzyme, attached to the cell surface, cuts the polymer into 
intermediate sized fragments of approximately 25 disaccharide units. These fragments are then internalized and passed to early lysosomes for further degrada-
tion by HYAL 1 [1, 8, 9] followed by further cleavage by the lysosomal acid exoglycosidases, β-glucuronidase and N-acetyl glucosaminidase. The single sug-
ars are then able to pass out of the lysosomes into the cell cytoplasm, where they participate in other carbohydrate pathways.  
eHA molecule (10,000 repeats) could be spread to 10 µm if stretched from end to end, a length similar to the diameter of a human erythrocyte [10]. 
fThe hydrodynamic diameter, equal to approximately 0.5 µm (Rh ≈ 263 nm), of even a 10 MDa HA molecule is able to flow readily through blood capillaries. 
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tions, lubricates joints, is involved in chondroprotection 
and functions as a space filling molecule and volume 
expander [1, 21-24]. HA is also associated with a vari-
ety of other processes including inflammation, immune 
regulation and malignant transformation [25-28]. In 
fact, the aggressiveness of human cancers often corre-
lates with levels of HA [29]. 
The sizes of HA macromolecules often determine 
their biological functions. Under normal conditions, 
HA is of high molar mass (mean molar mass greater 
than 5×105 Da) and possesses space filling, anti-
angiogenic, anti-inflammatory and immuno-suppre-
ssive properties. The high-molar-mass HAs usually 
occur in normal health tissues. Medium-sized-HA-
chains (mean molar mass ranging from 2×104 to 1×105 
Da) participate in ovulation, embryogenesis, and 
wound repair. However, under pathological conditions, 
HA can be degraded to oligosaccharides composed of 
15-50 repeating disaccharide units. Such oligosaccha-
rides are highly inflammatory, immuno-stimulatory and 
angiogenic, a reflection of tissues under stress. On the 
contrary, very small HA oligomers (400-4,000 Da) ap-
pear to mollify the severity of such reactions and are 
anti-apoptotic and able to induce the production of heat 
shock proteins [30, 31].  
HA as a large polymer is also present at elevated 
levels in many malignant tumors and, in some cases, is 
an accurate predictor of patient morbidity. For exam-
ple, experimental overexpression of HA synthases in 
human tumor cells results in elevated HA production, 
causes increased tumor growth in vivo [32, 33]. On the 
other hand, oligosaccharides of HA may inhibit growth 
of tumors via competing for endogenous polymeric 
HA, replacing high-affinity, multivalent receptor inter-
actions with low affinity, low-valency interactions. HA 
oligosaccharides significantly inhibit cell proliferation, 
motility, invasiveness in LM-8 murine osteosarcoma 
cells and MG-63 human osteoblastic osteosarcoma 
cells by suppressing cell-associated ECM formation. In 
the studies, these effects were due to the presence of 
oligosaccharides longer than octasaccharides [34]. 
Taken together, it appears that HA length, despite 
the fact that it is a simple unadorned polymer, is an in-
formation-rich system [35]. 
RECENT INCREASED INTEREST IN HA  
Interest in HA has been increased steadily. There 
has been an increase in the number of HA-related pub-
lications (Fig. 2). Further increases are certain to occur 
following the dramatic observations made recently with 
Table 2. Concentrations of HA (µg/g) in various organs in man and other animal species [18]. 
Organ or fluid Human Sheep Rabbit Rat 
Umbilical cord 4100    
Synovial fluid 1400-3600 540 3890  
Dermis 200    
Vitreous body 140-338 260 29  
Lung  98-243  34 
Kidney   93-113 30 
Renal papillae   250  
Renal cortex   4  
Brain 35-115  54-76 74 
Muscle   27  
Intestine    44 
Thoracic lymph 8.5-18 1-34  5.4 
Liver   1.5 4 
Aqueous humor 0.3-2.2 1.6-5.4 0.6-2.5 0.2 
Urine 0.1-0.3    
Lumbar celebrospinal fluid 0.02-0.32    
Blood plasma/serum 0.01-0.1 0.12-0.31 0.019-0.086 0.048-0.26 
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the naked mole rat, Heterocephalus glaber. These ro-
dents (Fig. 1b, [36]) have a remarkable life span that 
exceeds 30 years, when that of rats and mice rarely ex-
ceeds 2-3 years. Cells from these animals also have an 
unusual resistance to malignant transformation [37]. 
Naked mole rats have a molar mass of HA in their cir-
culation and embedded in their tissues five-times that 
of other rodents. These results are reflected also in their 
isolated fibroblasts. They secrete high-molar-mass HA, 
resulting from the decreased activity of the hyaluroni-
dase enzymes that degrade HA and a unique sequence 
of the key enzyme involved in HA synthesis, the 
hyaluronan synthase 2 (HAS 2) [8, 9]. With genetic 
deletion of HAS 2 or over-expression of the hyaluroni-
dase 2 enzyme, these animals cease being resistant to 
malignant transformation and become readily able to 
form tumors [37].  
 
Fig. (2). Publishing activity regarding HA research during 
the past 10 years, as established using the ScienceDirect da-
tabase [24]. 
 
Human milk contains HA and its concentration is 
highest immediately after delivery. Treatment of epi-
thelium with physiologic levels of milk-derived HA 
increases intracellular expression of β-defensin and 
resistance to Salmonella [38]. Based on these results, 
milk HA enhances functional antimicrobial defense 
mechanisms of the intestinal epithelium being a media-
tor of maternal protection of newborns.  
It appears that HA is associated with important phe-
nomena critical for the quality of human life, such as 
protection of newborns, cancer resistance and increased 
longevity. This accounts for the recent increased inter-
est in HA. Pharmaceutical uses for HA and its deriva-
tives will certainly become key reagents for enhancing 
these parameters that have the potential for improving 
human life. 
BIOMEDICAL APPLICATIONS 
As a component of normal human tissues, HA has 
been promoted as a biomaterial scaffold for applica-
tions for regenerative medicine and in tissue engineer-
ing [2, 39-41]. Solutions of HA have remarkable prop-
erties. Among these are viscoelasticity, biocompatibil-
ity, bioreactivity, non-immunogenicity, non-thrombo-
genicity, biodegradability, and hygroscopicity. These 
characteristics permit their use in a wide range of ap-
plications, including biomedical, cosmetic, and food 
industries [40].  
However, important properties of HA such as high 
water solubility at room temperature and very rapid 
rates of turnover and elimination can also be a barrier 
for its application as a scaffold for the lack of integrity 
of structure. To eliminate these hindrances, techniques 
of crosslinking and HA modifications were developed 
[39-42]. The properties of HA are greatly enhanced 
with crosslinking, which produces a hydrogel. This 
facilitates formation of desired molecular orientations 
and shape, as well as techniques that allow delivery of 
therapeutic molecules directly into the host [43, 44]. 
HA can be cross-linked by covalently linking thiols 
(Extracel, HyStem), methacrylates and with tyramines 
(Corgel). Crosslinking of HA can be performed with 
formaldehyde (Hylan-A) or divinylsulfone (Hylan-B). 
HA biopolymers can be exposed to chemical modifica-
tions to all its functional groups (the carboxylacidic, 
hydroxyl and the N-acetyl groups) [2, 41]. Currently, 
water-soluble carbodiimide-, polyvalent hydrazide-, 
divinyl sulfone-, disulfide-, glutaraldehyde-, auto- and 
photo-crosslinking, crosslinking with polyfunctional 
epoxides of hydrogels, have been developed [2, 45, 
46]. Such chemical crosslinking of HA inhibits degra-
dation of the polymer in vivo and allows prolonged 
structural stability.  
Currently, the most widespread HA derived prod-
ucts on the market are benzyl esters of HA [45]. 
Burdick and Prestwich [2] have reviewed the prepara-
tion of thiol-, haloacetate-, hydrazide-, aldehyde-, and 
tyramine-modified HA and their applications in carti-
lage tissue engineering, cardiac repair, engineering of 
cardiac valves, molecule delivery, control of stem cells 
behavior. Moreover, hydrogels derived from HA may 
serve as biological activators to cells, whereas changes 
in cellular behavior are observed, including differentia-
tion of stem cells. 
Cross-linked HA polymers as well as HA-ester de-
rivatives are anticipated to become available for clini-
cal application in dermatology [47-49]. Reitinger and 
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Lepperdinger [50] report the development of a new 
composite biomaterial based on HA-hydrogel contain-
ing cross-linked fibronectin. A well-established system 
is thiolated HA (e.g. ExtracelTM, Glycosan BioSystems, 
Inc.). Köwitsch et al. [51] have examined the bioactiv-
ity of HA derivatives such as aldehyde-HA and thiol-
HA immobilized on model substrata such as amino-
terminated surfaces or on gold. The major drug deliv-
ery applications of HA, both biomedical applications 
and HA-based treatments are summarized in Table 3 
[18]. 
VISCOSEPARATION 
Cross-linked HA at various concentrations has ap-
plications in a number of fields of medicine [21, 39, 
41]. Modified HA-based solutions, e.g. Seprafilm Ad-
hesion Barrier (Genzyme Corp.), are routinely applied 
to minimize postsurgical adhesion formation as an anti-
adhesion material. Concerning to the design of cell 
non-adhesive surfaces, the mechanism of cell and sur-
face interaction should be considered. In case of adher-
ing cells to the surface of a material, several physico-
chemical reactions occur between the cells and the ma-
terial interface. Immediately after implanting a bioma-
terial into an organism or into contact with cell culture 
environments, protein adsorption to its surface occurs, 
which mediates the cell adhesion and also provides 
signals to the cell through the cell adhesion receptors, 
mainly integrins [52]. Modifications of HA structure 
lead to lowered water solubility. Such materials thus 
become more stable in a physiological environment 
[53].  
VISCOSUPPLEMENTATION 
Osteoarthritis is a chronic, degenerative disease that 
commonly afflicts tissues such as joints, cartilages, 
bones, synovium, ligaments and muscle [54, 55]. The 
concentration of HA in the SF of the normal human 
articular joint is 2.5-4.0 mg/mL. Under pathological 
conditions, the concentration of HA can fall precipi-
tously to values below 1.2 mg/mL. The molar mass of 
HA is also reduced resulting in solutions that are mark-
edly decreased in elasticity and viscosity.  
Intra-articular applications of sterile HA solutions, 
termed viscosupplementation, provide analgesic, ana-
bolic, chondro-protective and anti-inflammatory effects 
that diminish pain and disability and thus enhance 
function of joints, decrease cartilage degradation, and 
promote cartilage matrix biosynthesis. The use of vis-
cosupplementation for other joints, such as shoulder, 
hip, and ankle that are currently under investigation, 
has introduced the term “visco-induction”, indicating 
that clinical efficacy can be long-term observed (sev-
eral months), even though the mean-residence time for 
such intra-articularly introduced HA being only a few 
days [54-63].  
Japan and Italy were the first countries, where vis-
cosupplementation was applied in clinical practice 
(1980s), followed by Canada, Europe and the USA 
(1990s) [24]. Commercially available products for vis-
cosupplementation contain sodium HA of different mo-
lar masses. Synvisc®, also known as Hylan G-F 20 
(Genzyme Corp, Cambridge, MA, USA), is a prepara-
tion containing cross-linked HA (Hylan-B), while 
Hyalgan® (Fidia, Abano Terme, Italy) and Artz Dispo 
(Seikagaku, Tokyo, Japan) are the products containing 
HA of molar mass of 1 MDa. Other products are 
Monovisc (biscarbodiimide XL, Anika) and Gel-One 
(cinnamate XL, Seikagaku). 
The proposed mechanism underlying the therapeutic 
effects of intra-articularly introduced HA derivatives 
on symptomatic osteoarthritic joints are as follows: 1) 
Table 3. Summary of the drug delivery applications of HA [18]. 
Route Efficacy Therapeutic agents 
Ophthalmic Elevated ocular persistence of drug, which can lead to in-
creased bioavailability 
Pilocarpine, tropicamide, timolol, gentimicin, tobramicin, 
arecaidine polyester, (S)-aceclidine 
Nasal Bioadhesion resulting in increased bioavailability Xylometazoline, vasopressin, gentamicin 
Pulmonary Absorption enhancer and dissolution rate modification Insulin 
Parenteral Drug carrier and facilitator of liposomal entrapment Taxol, superoxide dismutase, human recombinant insu-
lin-like growth factor, doxorubicin 
Implant Dissolution rate modification Insulin 
Gene Dissolution rate modification and protection Plasmid DNA/monoclonal antibodies 
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maintenance of elasticity and viscous properties of the 
SF, 2) anti-inflammatory and anti-nociceptive effects 
and 3) normalization of HA synthesis by synoviocytes. 
The material acceptable for visco-supplementation 
should fulfill the following criteria: 1) tissue and blood 
compatibility, 2) permeability to low- and high-molar-
mass substances, 3) rheological properties similar to 
those of normal SF and 4) slowing elimination rates in 
order to maintain extended protection [54, 60].  
VISCOSURGERY 
Ophthalmology. In the eye, HA is present in lacri-
mal glands, the vitreous body, human tear fluid, cor-
neal epithelium and also in conjunctiva [24]. HA is 
used as a viscoelastic gel to support healing and regen-
eration of surgical wounds, to prevent damage of the 
endothelial layer of the cornea, to function as 
a lubricant, to eliminate physical damage of other tis-
sues, to maintain operative space and depth of the ante-
rior chamber. This is particularly important in anterior 
segment surgery, glaucoma surgery, and during corneal 
transplantation [42]. During implant surgery, when the 
intraocular pressure is high, HA reduces this pressure. 
Furthermore, HA increases corneal humidity due to 
elevated water retention on the corneal surface. Also, 
HA is used to treat syndrome of dry eye [24, 63].  
Ocular tissue deterioration can occur on a heredity 
basis or as a result of other pathophysiological proc-
esses. Currently increased attention is being paid to 
diabetic cataracts because of the rapid worldwide in-
crease of diabetes mellitus. Healon® (sodium hyaluro-
nate, a former product of the Swedish company Phar-
macia) was for a long time the only available material 
for visco-surgical procedures. Today, similar products 
are used world-wide in surgery as a soft instrument to 
remove cataract, glaucoma surgery, for posterior seg-
ment surgery, intraocular lens implantation and kerato-
plasty. Furthermore, it can be used for repositioning 
and unrolling of the retina following detachment, lysis 
of anterior synechiae and for separation of tissues and 
adhesions mechanically. The use of HA with contact 
lenses in several types of applications have been re-
ported in several studies [24]. Viscoat® by Cilco (USA) 
is a product applied for extraction of cataract and intra-
ocular lens implantation and it is produced as a combi-
nation of sodium HA and sodium chondroitin sulphate. 
Hyalistil®, a 0.2% HA solution produced by Sifi (Italy), 
is used to stabilize the tear film, to hydrate and lubri-
cate the cornea and is desirable in increasing the com-
fort when applying contact lenses. Blink Contacts, eye 
drops produced by AMO (USA), are for users of con-
tact lenses containing 0.15% HA [46, 64].  
VISCO-AUGMENTATION 
Otolaryngology. Properties of HA such as osmosis, 
viscoelasticity and space-filling ability are critical for 
voice production. HA directly affects the thickness and 
viscosity of vocal folds. Moreover, HA derivatives can 
be applied in visco-augmentation of vocal cords, for 
the treatment of glottal insufficiency and the repair of 
injured or scarred vocal cords. A short residence time 
of HA is however a main disadvantage of applying HA 
as a lamina propria bioimplant for the treatment of vo-
cal fold disorders. The HA mean-residence-time in the 
rabbit vocal fold is only 3-5 days. The solution is to 
modify the molecular structure of HA to prolong the 
material residence time [40]. One of the simplest hy-
drogels used for vocal fold augmentation is the divinyl-
sulfone cross-linked HA derivative Hylan-B which, in 
animal models, is found to be anti-inflammatory, non-
antigenic and non-toxic.  
To date, Hylan-B and its derivatives serve as a 
space filling hydrogel, whereas their only possible ap-
plication is by injection. Several clinical studies involv-
ing rheological studies and animal models support the 
mechanism of HA derivatives to be beneficial to re-
place a lamina propria for vocal fold scars and sulci 
[65, 66].  
COSMETIC APPLICATIONS 
About 50% of the total HA in humans occurs in skin 
[67]. HA therefore is a reasonable matrix component 
for enhancing dermal regeneration and augmentation 
[68]. The excellent moisturizing properties of HA are 
the basis of its inclusion in skin-care products [24, 40, 
47].  
Materials for deep augmentation injection into skin 
are temporary and permanent/long-term. Long-term or 
permanent injectable materials include calcium hy-
droxyapatite, autologous fat, (Radiesse™, Merz Phar-
ma GmbH, Germany), polydimethylsiloxane (or par-
ticulate silicone), and polytef paste (Teflon™). Among 
temporary injection materials rank collagen-based 
products (Cymetra™, Zyplast™, Cosmoplast/Cosmo-
derm™) bovine gelatin (Gelfoam™, Surgifoam™), 
and 1-carboxymethylcellulose (Radiesse Voice Gel™, 
Merz Aestetics, Germany). These materials differ in 
the endurance of integration, in their biocompatibility 
and specific viscoelastic properties. The injectable ma-
terials based on HA include Hylaform® (Genzyme 
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Corp., MA, USA) and Restylane™ (Q-med, Sweden) 
[45, 65].  
VISCOPROTECTION 
Wound healing. HA stimulates wound healing as 
can be demonstrated for tendon, bone, corneal, diabetic 
foot, nasal mucosal and venous leg ulcers [21]. HA 
participates in several stages of wound healing [69]. In 
an early stage, high-molar-mass HA is bound to fi-
brinogen during clot formation. In the adult, wound 
healing frequently results in scar formation. However, 
in fetal wounds, scar formation is inhibited by the pres-
ence of high-molar-mass HA [70]. This was demon-
strated in experimental fetal rabbit and fetal sheep 
models as well as in term infants following mid-
gestation in utero surgery [71].  
In 2011, Cutting [72] reported that in spite of posi-
tive effects of several HA-containing products on 
wound healing, some adverse effects were also ex-
pressed. This may be explained by possible wound in-
fections (empirical observations) associated with appli-
cation of some HA-based dressings. For this reason, the 
current author [72] reports application of a newly de-
veloped wound preparation that includes HA associated 
with an antimicrobial iodine-containing compound. 
This is a novel and innovative solution that has the po-
tential to provide improved clinical outcomes for com-
plex wound-healing situations. Fragmentation of high-
molar-mass HA occurs naturally within the wound. 
This leads to altered properties of the healing material 
that affects the potential benefits of topical applica-
tions. One option, in order to overcome this problem is 
esterification of the HA moieties. The product thus be-
comes more resistant to its degradation by hyaluroni-
dases. However, such esterification increases the hy-
drophobicity of the HA-based material.  
Another approach also uses the aforementioned HA-
iodine complex. Contipro Pharma Inc. (Czech Repub-
lic) produces Hyiodine®, a wound-healing product for a 
wide range of chronic and acute wounds. Its efficacy is 
based on the synergistic effect of HA and iodine [73].  
Combinations of HA with other biomaterials for 
particular wound healing situations have been studied 
in the past few years. HA conjugated with gelatin or 
collagen in the presence or absence of growth factors 
such as EGF (epidermal growth factor) or bFGF (basic 
fibroblast growth factor) showed promising results in 
experimental wound-healing models [74-81]. The an-
timicrobial HA-based wound dressings based on HA 
are formulated combining HA with antibiotics, nano-
silver or mixed with antimicrobial polymers such as 
chitosan [82-85]. 
Hunt and Grover [86] report on the application of 
biopolymer gel encapsulation in regenerative medicine. 
Properties and applications of biopolymer gels based 
on alginate, fibrin, collagen, agarose, gelatin and HA 
are described. Table 4 summarizes some of the func-
tions of HA in the several steps of wound healing [69].  
HYALURONAN LABELING FOR DIAGNOSTIC 
PURPOSES 
Lindqvist et al. [87] developed a HA-loading test 
for assessment of HA kinetics to use it in patients with 
liver and joint diseases. The test describes the metabo-
lism of HA but cannot define the specific contribution 
of different organs. A method for labelling of HA with 
the short-lived positron-emitting radionuclide 11C was 
applied in healthy individuals and in patients suffering 
from liver diseases. The finding is that positron elec-
tron topography with [11C] HA may be an accurate 
method to assess liver dysfunction, when endothelial 
cell function is impaired. 
Near-infrared (NIR) fluorescence was used for func-
tional lymphatic imaging in the abdomen and anterior 
hindlimb of anesthetized, intact Yorkshire swine [88]. 
The results show the capability to image the immediate 
trafficking of indocyanine green from the plexus, 
through the vessels and lymphangions, and to the su-
perficial mammary, sub iliac, and middle iliac lymph 
nodes, which were located as deep as 3 cm beneath the 
tissue surface. The results suggest that microgram 
quantities of NIR optical imaging agents and their con-
jugates have a potential to image lymph function in 
patients suffering from lymph-related disorders. 
Jadhav et al. [89] synthesized a macrocyclic 68Ga-
NOTA-chelated oligonucleotide-HA conjugates using 
a solid supported technique to introduce NOTA-
chelator (NOTA - 1,4,7-triazacyclononane-N,N',N''-
triacetic acid) into the 3′-terminus and a copper-free 
strain promoted azide alkyne cycloaddition to HA/olig-
onucleotide conjugation. As a method positron emis-
sion tomography was used in healthy rats to monitor 
distribution kinetic studies and a potential of HA-
induced targeting of oligonucleotides into rats afflicted 
with myocardial infarction was determined. 
DRUG DELIVERY 
A number of studies report that HA facilitates the 
prolonged residence and the increased bioavailability 
of certain drug molecules. Typical examples are pilo-
carpine and vasopressin. HA of higher size rather than
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Table 4. Functions of HA during wound healing [69].  
Phases Effects 
Binding to fibrinogen to initiate clotting pathway 
Ensuring inflammatory cell migration 
Creating edema to allow cell infiltration 
Inflammatory phase 
Inhibiting neutrophil migration to dampen inflammatory response 
Accumulating of fibroblasts to wound site  
Filling in gaps of newly formed extracellular matrix, creating cushioning and structural 
organization 
Stimulating matrix metaloproteinases for angiogenesis 
Proliferative phase 
Promoting keratinocyte migration and proliferation 
Remodeling phase Contribution to normal and pathological scarring 
Table 5. Practical applications of visco-elastic solutions of HA or its gels [18, 40].  
Application Treatment 
Viscosupplementation To replace or supplement tissue fluids, such as replacement of SF in painful arthritis, and to relieve pain 
Viscosurgery To protect delicate tissues and provide space during surgical manipulations, as in ophthalmological sur-
geries 
Viscoaugmentation To fill and augment tissue spaces, as in skin, sphincter muscles, vocal and pharyngeal tissues  
Viscoseparation To separate connective tissue surfaces traumatized by surgical procedures or injury, in order to prevent 
adhesions and excessive scar formation 
Viscoprotection To protect healthy, wounded, or injured tissue surfaces from dryness or noxious environmental agents, 
and to promote the healing of such surfaces  
Drug delivery Matrix and tissue engineering 
 
the low-molar-mass HA species supports increased 
drug bioavailability. HA as a non-immunogenic sub-
stance is used in parental/pulmonary drug delivery sys-
tems to allow constant release and longer retention of 
the therapeutic agents. For example, the anti-cancer 
drug, taxol, when linked to HA was observed to target 
breast cancer, human colon and ovarian cell lines in 
vitro selectively. Furthermore, HA was used to dis-
cover an implantable delivery system for long-term 
delivery of anti-inflammatory and antibiotic drugs in 
vivo [21].  
HA can be also included in nasal, ophthalmic and 
parenteral drug delivery. Novel applications, including 
pulmonary implantation and gene delivery, are summa-
rized in Table 5 [18, 40]. Kogan et al. [40] reported that 
HA can be either directly conjugated to drugs or used 
for preparation of microcapsules to enhance drug de-
livery. HA is also involved in improving biocompati-
bility of chitosan microspheres, which function as cap-
sules for drug delivery. It is apparent that HA has mul-
tiple uses, both direct and indirect, in the pharmaceuti-
cal industry. 
CONCLUSION 
New insights into mammalian longevity and malig-
nancy were discovered recently in research on the na-
ked mole rat. These observations can play key roles in 
future treatment of human cancer. They will also facili-
tate approaches to improve quality of life while extend-
ing human longevity. The new treatment modalities 
and therapeutic applications will involve the production 
of high-molar-mass HAs. These considerations promp-
ted the current overview, anticipating opportunities for 
new techniques for preparation and isolation of HA, for 
modifications of structure that improve availability and 
resistance to degradation. Such materials will stimulate 
many new investigations.  
In the future, more attention will be devoted to en-
zymatic production of HA. A huge number of modifi-
cations of HA can be performed with the aim of en-
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hancing the quality of the material for medicine, phar-
maceuticals, cosmetics as well as for industrial produc-
tion. We are only now beginning to appreciate the large 
numbers of applications for this versatile molecule as 
well as the innumerable modifications possible with 
this multifaceted, highly ionic polymer.  
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